Roggwil, November 12, 2020 – The study agreed with Charité in Berlin on tinniwell cannot currently be started due to the pandemic situation. There is still no return to unrestricted on-site research there. As soon as the study can be started, we will publish this here without delay.

++ About Resaphene Suisse AG

Resaphene Suisse AG, based in Roggwil, Switzerland, is a medical technology company founded in 2015 and has been marketing a tinnitus therapy device under the name tinniwell since 2016. Other sales companies are Resaphene Deutschland GmbH in Constance, Resaphene UK Ltd. in London, and Resaphene US LLC in the USA.

++ Contact for inquiries:

Resaphene Suisse AG
Ms. Anke Rauterkus (Chief Executive Officer)
Bahnhofplatz 5
9322 Egnach
Switzerland
T. +41 714500668
a.rauterkus@resaphene.ch